All articles tagged with #ulcerative colitis
Researchers identified specific antibody patterns in blood samples that appear up to ten years before the diagnosis of inflammatory bowel disease (IBD). The study, involving 500 US military personnel, found distinct immune signals for Crohn's disease and ulcerative colitis, suggesting potential for earlier detection. While not yet a clinical test, these findings offer hope for preventing gut damage before symptoms arise.
A Bozeman mother and her 16-year-old son sued Chipotle after a nationwide salmonella outbreak tied to jalapeños; the son fell ill July 14 after dining at a Bozeman Chipotle on July 9 and was later diagnosed with ulcerative colitis, as health officials report more than 300 cases across 25 states linked to the outbreak and involving Mexican-style chains like Chipotle and Qdoba.
Abivax’s late‑stage data on obefazimod show malignancies at rates consistent with ulcerative colitis background risk, easing prior cancer concerns and sending the stock up about 34%; the company reiterates plans to file an FDA NDA in Q4 2026, with a Crohn’s trial due mid‑2027 and roughly 37% of initial non‑responders achieving remission after ~10 months on 50 mg. Analysts like Jefferies call the update supportive but warn that generalist investors may still hesitate amid cancer risk, cash needs, and takeover chatter.
Merck's tulisokibart, an anti-TL1A monoclonal antibody, met the Phase 3 ATLAS-UC induction-only study’s primary endpoint of clinical remission (Modified Mayo Score at week 12) and key secondary endpoints in adults with moderately to severely active ulcerative colitis, with no safety concerns reported. This marks the first successful Phase 3 remission signal for an anti-TL1A therapy, and results will be presented alongside data from the ongoing Study 1 and shared with regulatory authorities, highlighting the approach's potential against immuno-fibrosis.
Abivax’s ulcerative colitis therapy obefazimod showed high remission rates in a 580-patient Phase 3 maintenance trial, with about 51% remission at both 25 mg and 50 mg doses over 44 weeks versus 10.4% with placebo, suggesting strong efficacy. However, the company reported a few cancer cases among treated patients, raising safety concerns and sending shares lower after the results were disclosed.
A large UK study (PREdiCCt) of over 2,600 people with inflammatory bowel disease found that higher baseline fecal calprotectin, a noninvasive stool marker of gut inflammation, strongly predicted future flares even when patients were symptom-free—UC patients with elevated calprotectin faced about a 34% objective flare risk within 2 years vs ~11% with low levels. Habitual meat intake was linked to nearly double the risk of ulcerative colitis flares, while other dietary factors showed no consistent associations; there was no such meat-flare link for Crohn’s disease. The results point to a potential for biomarker- and diet‑guided, personalized IBD management, using stool tests plus dietary data to forecast relapses months ahead. However, the study is observational and cannot prove causation, and local validation may be needed before widespread adoption.
A 35-year-old Texas mother with a long history of ulcerative colitis is diagnosed with an aggressive colorectal cancer after childbirth. She undergoes three surgeries to remove her large intestine and reconstruct a J-pouch, followed by a six-month chemotherapy course; she has remained cancer-free since 2013 and reports a markedly improved quality of life despite ongoing dietary adjustments.
Researchers have discovered that smoking produces metabolites like hydroquinone that promote mouth bacteria such as Streptococcus to grow in the gut, which can reduce inflammation in ulcerative colitis. This finding suggests potential treatments using probiotics or prebiotics to mimic smoking's protective effects without the associated health risks.
A study shows that pro-inflammatory diets can worsen IBD symptoms, with those consuming such diets being up to three times more likely to experience moderate to severe disease, emphasizing the importance of an anti-inflammatory diet for managing IBD.
Inflammatory bowel disease (IBD), affecting up to 3.1 million adults in the U.S., is a chronic condition where the immune system attacks the intestines, causing inflammation and damage. Diagnosis involves medical history, physical exams, lab tests, and imaging like endoscopy or MRI. IBD differs from irritable bowel syndrome (IBS), which has similar symptoms but no underlying disease. Managing IBD requires a team approach to find effective medication and lifestyle strategies to prevent flare-ups and address related health issues.
Research shows that smoking helps alleviate ulcerative colitis by promoting mouth bacteria like Streptococcus to grow in the gut, triggering an immune response that reduces inflammation. This effect is linked to metabolites like hydroquinone produced during smoking, which could lead to alternative treatments such as probiotics or prebiotics, avoiding smoking's health risks.
Researchers at the Francis Crick Institute in London have discovered a key driver of inflammatory bowel disease (IBD) and other immune disorders, potentially leading to new treatments using existing drugs. This breakthrough could significantly impact the lives of millions suffering from conditions like Crohn's disease and ulcerative colitis.
Michael Sheridan, diagnosed with ulcerative colitis in 2009, experienced a sudden flare-up in 2019, leading to a stage 3 colon cancer diagnosis in December 2020. After undergoing a sigmoidectomy and chemotherapy, he is now cancer-free. The experience prompted him to advocate for informed consent in his treatment and cherish time with his family. Inflammatory bowel disease patients should be vigilant about symptoms and undergo regular colonoscopies due to the increased risk of colorectal cancer.
Michael Sheridan, diagnosed with ulcerative colitis in 2009, experienced a sudden flare-up in 2019, leading to a stage 3 colon cancer diagnosis in December 2020. After undergoing a sigmoidectomy and chemotherapy, he is now cancer-free. His experience highlights the increasing incidence of colon cancer in young people, particularly those with inflammatory bowel disease, and the importance of regular colonoscopies for early detection.
Pfizer's drug Velsipity, used to treat ulcerative colitis, has been approved by the European Commission for patients aged 16 or older who did not respond well to previous treatments. The approval, based on successful late-stage trials, allows the drug to be available in all 27 EU countries. With an estimated 2.6 million people in Europe living with ulcerative colitis, Velsipity is expected to compete with Bristol Myers Squibb's Zeposia and has also sought regulatory approvals in other countries.